HEFEI, China, Nov. 18, 2025 /PRNewswire/ — Kangpu Biopharmaceuticals announced today that the company will deliver a poster presentation to highlight the Phase I clinical trial results of epaldeudomide (KPG-818) for the treatment of hematological malignancies at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, Florida, USA.
Poster Title: KPG-818, a Novel Cereblon (CRBN) Modulator, in Patients with Hematological Malignancies: Results of a Phase I, Open-Label, Multiple Ascending Dose Study
Poster Number: 5809
Poster Category: 654. Multiple Myeloma: Pharmacologic Therapies: Poster III
Presenter: Dr. Aaron Rosenberg, MD, UC Davis Comprehensive Cancer Center, California, United States
Presentation Time: 6:00-8:00 PM, December 8 (Local Time)
Location: OCCC – West Halls B3-B4
The study is a multicenter, open-label, multiple ascending dose Phase I clinical trial (NCT04283097) completed in the United States to evaluate the safety, tolerability, pharmacokinetics, along with preliminary efficacy of epaldeudomide in combination with dexamethasone in adults with relapsed/refractory multiple myeloma, or as monotherapy in other selected hematologic malignancies, and to determine the recommended Phase II dose. Epaldeudomide demonstrated favorable pharmacokinetic characteristics, good safety and tolerability, and promising efficacy. The overall response rate in the heavily pre-treated multiple myeloma patients was 50% with a disease control rate (including stable disease) of 94%. No febrile neutropenia of any grade was observed, and no peripheral neuropathy events of any grade was reported.
Epaldeudomide is a novel molecular glue modulator of the E3 ubiquitin ligase complex CRL4-CRBN. It showed high cereblon (CRBN) binding affinity and potent degradation of Aiolos (IKZF3) and Ikaros (IKZF1), two members of the Ikaros family of zinc-finger transcription factors associated with B-cell development. Epaldeudomide possesses remarkable broad-spectrum immunomodulatory effects, anti-angiogenic, and anti-tumor effects.
For more information about the 67th ASH Annual Meeting, please visit https://www.hematology.org/.
About Kangpu BiopharmaceuticalsKangpu Biopharmaceuticals, Ltd. is a clinical-stage company focused on the discovery and development of innovative molecular glue-based therapeutics for the treatment of autoimmune diseases, solid tumors, hematologic malignancies and inflammatory disorders. Kangpu has developed a robust pipeline of potential first-in-class and best-in-class drug candidates based on proprietary technology platforms, including NeoMIDES®, gDACS®, and X-SYNERGY®.
For more information, please visit www.KangpuGroup.com.
This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
